Telmisartan
Reading File
Finding Sources
Searching PubMed
telmisartan
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Excellent - I now have rich, detailed information from multiple authoritative sources. Let me compile a comprehensive answer.
Telmisartan (MICARDIS)
Drug Class & Chemical Features
Telmisartan is a nonpeptide, noncompetitive Angiotensin II Receptor Blocker (ARB) - specifically classified as a nonbiphenyl tetrazole derivative that incorporates a carboxylic acid as its biphenyl acidic group. It has high specificity and high receptor affinity for the AT1 receptor, and its antagonism is functionally insurmountable - meaning blockade is sustained even when endogenous AngII levels rise.
ARBs as a class are >10,000-fold more selective for AT1 vs AT2 receptors.
Mechanism of Action
Telmisartan blocks AT1 receptors, thereby inhibiting virtually all biological effects of Angiotensin II:
- Vascular smooth muscle contraction
- Rapid and slow pressor responses
- Aldosterone secretion
- Vasopressin release
- Adrenal catecholamine release
- Renal tubular sodium reabsorption
- Cellular hypertrophy and hyperplasia (cardiac remodeling)
- Enhancement of noradrenergic neurotransmission
Unlike ACE inhibitors, ARBs do NOT block chymase-mediated AngII formation - instead they block AT1 regardless of how AngII was formed. They also allow continued AT2 receptor activation (which may be cardioprotective), and they do not inhibit bradykinin breakdown - hence no cough (a key advantage over ACE inhibitors).
Pharmacokinetics
| Parameter | Telmisartan |
|---|---|
| Onset of action | ~3 hours |
| Peak plasma level | 0.5 to 1 hour after oral dose |
| Duration of action | 24 hours; may persist up to 7 days after stopping |
| Plasma half-life | ~24 hours (longest among ARBs) |
| Bioavailability | Moderate; food has minimal effect |
| Metabolism | <3% hepatically metabolized; mainly biliary secretion of intact drug |
| Elimination | Primarily biliary (not renal) |
| Dialyzability | Not dialyzable |
| Renal impairment | No dose adjustment needed |
| Hepatic impairment | Clearance reduced - use with caution |
Sex difference: Women achieve plasma levels 2-3x higher than men, but this does not correlate with differences in BP response.
Dosing
- Starting dose: 40 mg once daily
- Usual daily dose: 40-80 mg once daily
- Given as a single daily dose (very long half-life makes once-daily dosing reliable)
Approved Indications
- Hypertension - first-line or combination therapy
- Heart failure (with reduced ejection fraction) - as an ARB alternative when ACE inhibitors are not tolerated
- Cardiovascular risk reduction - studied in the landmark ONTARGET trial (Telmisartan vs Ramipril vs combination in high-risk patients) and the TRANSCEND trial (ACE-inhibitor intolerant patients)
There is also specific evidence for antipsychotic-associated hypertension, where valsartan and telmisartan have shown particular efficacy - Maudsley Prescribing Guidelines, 15th ed.
Renal Effects
ARBs, including telmisartan, block intrarenal AT1 receptors located on:
- Afferent and efferent arterioles
- Glomerular mesangial cells
- Proximal and distal tubule cells
- Collecting ducts and podocytes
Key renal effects include natriuresis (direct proximal tubule inhibition of sodium reabsorption), reduced tubuloglomerular feedback sensitivity, and proteinuria reduction in diabetic nephropathy. No dose adjustment is required in kidney disease. - Brenner & Rector's The Kidney
ARB vs ACE Inhibitor - Key Differences
| Feature | ARBs (Telmisartan) | ACE Inhibitors |
|---|---|---|
| AngII generation | Not blocked (chymase path active) | Partially blocked |
| AT1 blockade | Complete, regardless of AngII source | Indirect only |
| AT2 activation | Permitted (increased AngII activates AT2) | Limited |
| Bradykinin breakdown | Not affected | Inhibited - causes cough |
| Dry cough | Absent | Common side effect |
| Angioedema | Rare | Rare but more common |
Adverse Effects & Contraindications
- Hyperkalemia - due to reduced aldosterone secretion (monitor K+, especially with K-sparing diuretics or in renal impairment)
- Hypotension - especially in volume-depleted patients
- Acute kidney injury - in bilateral renal artery stenosis or severe volume depletion
- Teratogenicity - Contraindicated in pregnancy (fetal renal dysplasia, oligohydramnios, skull ossification defects - Category D/X)
- Hepatic impairment - clearance is reduced; use with caution
- No dose adjustment for renal impairment (unlike many other drugs)
- Do NOT combine with ACE inhibitors (dual RAS blockade increases AKI and hyperkalemia without added CV benefit - per ONTARGET data)
Unique Features of Telmisartan
- Longest half-life (~24 h) of all ARBs - provides sustained 24-hour BP control with once-daily dosing, and lingering effect up to 7 days post-discontinuation
- Primarily biliary elimination - safe in renal failure
- Partial PPAR-γ agonist activity - telmisartan has mild insulin-sensitizing/metabolic effects (studied in metabolic syndrome), a feature not shared by most ARBs
- Studied in the largest ARB outcome trials (ONTARGET, TRANSCEND)
Recent Evidence (PubMed, 2024-2026)
A 2025 population pharmacokinetics meta-analysis (PMID 39808372) characterized telmisartan PK across healthy subjects and hypertensive patients, confirming its long half-life and dose-proportional exposure. A 2024 network meta-analysis of six ARBs (PMID 38861046) found comparable efficacy among ARBs for BP lowering, with azilsartan showing slight superiority, while telmisartan remained among the most widely used for once-daily dosing reliability.
Sources: Brenner & Rector's The Kidney (8e) | Goodman & Gilman's Pharmacological Basis of Therapeutics | Lippincott Illustrated Reviews: Pharmacology | Maudsley Prescribing Guidelines (15e)
This is a shared conversation. Sign in to Orris to start your own chat.